Q-Line Biotech Limited (NSE:QLINE)
India · Delayed Price · Currency is INR 611.65
+9.90 (1.65%)
At close: Oct 14, 2026
Q-Line Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 3,417 | 3,131 | 2,036 | 1,827 | 3,042 |
Other Revenue | - | - | - | - | -0 |
| 3,417 | 3,131 | 2,036 | 1,827 | 3,042 | |
Revenue Growth | 9.13% | 53.77% | 11.44% | -39.92% | 77.46% |
Cost of Revenue | 1,347 | 1,485 | 937.52 | 886.63 | 1,476 |
Gross Profit | 2,071 | 1,646 | 1,099 | 940.73 | 1,565 |
Selling, General & Admin | 432.18 | 333.79 | 267.19 | 265.82 | 252.13 |
Other Operating Expenses | 576.36 | 536.51 | 445.1 | 325.41 | 566.92 |
Operating Expenses | 1,116 | 940.64 | 751.67 | 613.23 | 832.01 |
Operating Income | 954.06 | 705.65 | 347.27 | 327.5 | 733.32 |
Interest Expense | -189.16 | -135.21 | -58.98 | -30.75 | -27.16 |
Interest & Investment Income | 46.65 | 34.61 | 21.9 | 18.67 | 6.96 |
Earnings From Equity Investments | - | 35.29 | 128.03 | 107.15 | - |
Currency Exchange Gain (Loss) | -72.47 | -16.26 | -4.34 | -9.82 | - |
Other Non Operating Income (Expenses) | -4.28 | -14.2 | -3.77 | -7.21 | -0.32 |
EBT Excluding Unusual Items | 734.81 | 609.88 | 430.11 | 405.53 | 712.81 |
Gain (Loss) on Sale of Assets | 0.61 | -0.26 | 3.94 | 0.02 | - |
Other Unusual Items | -9.92 | -226.95 | - | - | - |
Pretax Income | 725.5 | 382.67 | 434.04 | 405.55 | 712.81 |
Income Tax Expense | 168.28 | 190.56 | 89.6 | 84.58 | 162.65 |
Earnings From Continuing Operations | 557.22 | 192.11 | 344.45 | 320.97 | 550.16 |
Minority Interest in Earnings | - | - | 0.05 | - | - |
Net Income | 557.22 | 192.11 | 344.49 | 320.97 | 550.16 |
Preferred Dividends & Other Adjustments | -9.92 | -169.7 | - | - | - |
Net Income to Common | 567.13 | 361.81 | 344.49 | 320.97 | 550.16 |
Net Income Growth | 56.75% | 5.03% | 7.33% | -41.66% | 299.63% |
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 15 |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 15 |
Shares Change | 1.70% | - | - | 5.00% | 0.00% |
EPS (Basic) | 35.41 | 22.97 | 21.87 | 20.38 | 36.68 |
EPS (Diluted) | 35.41 | 22.97 | 21.87 | 20.38 | 36.68 |
EPS Growth | 54.13% | 5.03% | 7.33% | -44.44% | 299.62% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -195.38 | -528.9 | -730.8 | -12.98 | - |
Free Cash Flow Per Share | -12.20 | -33.58 | -46.40 | -0.82 | - |
Gross Margin | 60.59% | 52.57% | 53.96% | 51.48% | 51.46% |
Operating Margin | 27.92% | 22.53% | 17.05% | 17.92% | 24.11% |
Profit Margin | 16.60% | 11.55% | 16.92% | 17.57% | 18.09% |
Free Cash Flow Margin | -5.72% | -16.89% | -35.89% | -0.71% | - |
EBITDA | 1,043 | 775.99 | 386.34 | 348.66 | 746.28 |
EBITDA Margin | 30.51% | 24.78% | 18.97% | 19.08% | 24.53% |
D&A For EBITDA | 88.58 | 70.34 | 39.06 | 21.16 | 12.96 |
EBIT | 954.06 | 705.65 | 347.27 | 327.5 | 733.32 |
EBIT Margin | 27.92% | 22.53% | 17.05% | 17.92% | 24.11% |
Effective Tax Rate | 23.20% | 49.80% | 20.64% | 20.86% | 22.82% |
Revenue as Reported | - | - | 2,064 | 1,848 | 3,056 |
Advertising Expenses | 8.01 | 8.61 | 11.23 | 8.73 | 0.28 |